A gold-based inhibitor of oxidative phosphorylation is effective against triple negative breast cancer

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• Triple-negative breast cancer (TNBC) presents significant challenges due to metabolic heterogeneity and limited therapeutic options.
• Targeting cancer cell metabolism is a promising strategy for developing new TNBC treatments.
• Organometallic gold(III) compounds have shown potential in modulating cellular respiration.

Purpose of the Study:

• To investigate the efficacy of a gold(III) dithiocarbamate (AuDTC) compound in targeting TNBC.
• To determine if AuDTC can modulate mitochondrial function and induce oxidative damage in cancer cells.
• To evaluate the therapeutic potential of AuDTC in preclinical TNBC models.

Main Methods:

• Design and synthesis of organometallic Au(III) compounds.
• In vitro assessment of AuDTC's effect on cancer cell mitochondria and oxidative stress.
• In vivo evaluation of AuDTC efficacy in TNBC mouse models with varying metabolic profiles.

Main Results:

• The AuDTC compound effectively induced mitochondrial dysfunction and oxidative damage in cancer cells.
• AuDTC demonstrated efficacy in TNBC mouse models, particularly those reliant on oxidative phosphorylation.
• Systemic delivery of AuDTC showed therapeutic potential in established TNBC models.

Conclusions:

• AuDTC is an effective modulator of mitochondrial respiration with significant anticancer activity against TNBC.
• Targeting metabolic pathways, specifically mitochondrial respiration, represents a viable therapeutic strategy for TNBC.
• AuDTC warrants further clinical development for the treatment of triple-negative breast cancer.